HIKMA PHARMACEUTICALS PUBLIC LIMITED COMPANY Environmental Analytics
Environmental and financial analysis dashboard for HIKMA PHARMACEUTICALS PUBLIC LIMITED COMPANY. Industry: MANUFACTURING
Company Overview for HIKMA PHARMACEUTICALS PUBLIC LIMITED COMPANY
Highlights
Showing data for FY2023
Operational Environmental Cost
$30m
Operational Environmental Cost Intensity
1.02%
Total Environmental Cost
$248m
Total Environmental Cost Intensity
8.45%
ΔOperational Environmental Cost (2020-2023)
$2.96m
Decoupling Rate (2020-2023)
4.04%
Adjusted EBITDA
$534m
Adjusted EBITDA Margin
18%
Environmental cost statement
Showing data for FY2023
| USD MM | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|
| OPERATIONAL SOCIAL COST OF CARBON | ||||
| -1.97% | 7.02% | 7.80% | ||
| 0.38% | 0.35% | 0.38% | 0.35% | |
| -3.74% | 0.35% | 13.77% | ||
| 0.77% | 0.69% | 0.71% | 0.67% | |
| $27m | $26m | $27m | $30m | |
| -3.15% | 2.60% | 11.68% | ||
| 1.16% | 1.04% | 1.09% | 1.02% | |
| INDIRECT SOCIAL COST OF CARBON | ||||
| 31099.07% | 27.19% | 13.67% | ||
| 0.02% | 6.00% | 7.82% | 7.43% | |
| 543.81% | 23.55% | 13.43% | ||
| 1.18% | 7.04% | 8.92% | 8.45% | |
All figures are denominated in millions of USD. USD is the base currency used to monetize, other currency equivalents are calculated using end of year exchange rates. Scope 2: Social Cost of Carbon is calculated using market-based emissions data. | ||||
Environmental cost bridge
Showing data for FY2023
Integrated financial analysis
Highlights
Showing data for FY2023
Adjusted EBITDA Margin
18%
Adjusted EBIT Margin
11%
EV / Adjusted EBITDA
Company Value: Placeholder
Industry Average: Placeholder
Coming soon
EV / Adjusted EBIT
Company Value: Placeholder
Industry Average: Placeholder
Coming soon
Integrated income statement
Showing data for FY2023
| USD MM | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|
| INCOME STATEMENT | ||||
$2,341m | $2,516m | $2,456m | $2,940m | |
| 7.48% | -2.40% | 19.71% | ||
$1,636m | $1,783m | $1,983m | $2,375m | |
| 69.88% | 70.86% | 80.73% | 80.80% | |
$705m | $733m | $473m | $564m | |
| 30.12% | 29.14% | 19.27% | 19.20% | |
$614m | $591m | $285m | $362m | |
| 26.23% | 23.50% | 11.60% | 12.31% | |
| ENVIRONMENTAL COST DATA | ||||
$27m | $26m | $27m | $30m | |
| 1.16% | 1.04% | 1.09% | 1.02% | |
| FINANCIAL DATA ADJUSTED FOR OPERATIONAL ENVIRONMENTAL COST | ||||
$678m | $707m | $446m | $534m | |
| 28.96% | 28.10% | 18.17% | 18.18% | |
$587m | $565m | $258m | $332m | |
| 25.07% | 22.46% | 10.51% | 11.29% | |
All figures are denominated in millions of USD. USD is the base currency used to monetize, other currency equivalents are calculated using end of year exchange rates. | ||||
Environmental EBITDA bridge
Showing data for FY2023
Industry benchmark
MANUFACTURE OF PHARMACEUTICAL PREPARATIONS
Scope 1 (% of Sales)
0.35%
Scope 2 (% of Sales)
0.67%
Operational Environmental Cost Intensity
1.02%
Scope 3 (% of Sales)
7.43%
Total Environmental Cost Intensity
8.45%
Selected peer group
Showing data for FY2023
NAME | COUNTRY | OPERATIONAL ENV. COST | OPERATIONAL ENV. COST INTENSITY |
|---|---|---|---|
HIKMA PHARMACEUTICALS PUBLIC LIMITED COMPANY | GB | $30m | 1.02% |
Loading similar companies data...
Industry distribution
Showing data for FY2023
Note: Outliers are calculated using the 1.5 * IQR method, where values outside Q1 - 1.5 * IQR and Q3 + 1.5 * IQR are considered outliers.
Estimated Social Cost of Carbon Scope 3 breakdown
Percentage breakdown of Social Cost of Carbon Scope 3 into various categories
Showing data for FY2023
SCOPE 3 CATEGORY | Company (USD) | Company % | Industry Avg (USD) | Industry Avg % |
|---|---|---|---|---|
Purchased goods (1 & 2) | $81m | 46.16% | N/A | N/A |
Energy-related activities (3) | $8m | 4.61% | N/A | N/A |
Upstream transportation (4) | $30m | 17.23% | N/A | N/A |
Waste (5) | $2m | 1.04% | N/A | N/A |
Business travel (6) | $1m | 0.65% | N/A | N/A |
Commuting (7) | $0m | 0.26% | N/A | N/A |
Upstream leased assets (8) | N/A | N/A | N/A | N/A |
Downstream transportation (9) | $21m | 12.15% | N/A | N/A |
Processing of products (10) | $0m | 0.02% | N/A | N/A |
Use of products (11) | N/A | N/A | N/A | N/A |
Final treatment of products (12) | $31m | 17.88% | N/A | N/A |
Downstream leased assets (13) | N/A | N/A | N/A | N/A |
Franchises (14) | N/A | N/A | N/A | N/A |
Investments (15) | N/A | N/A | N/A | N/A |
Total | $175m | 100.00% | $0m | 100.00% |
Scope 3 breakdown visualization
Showing data for FY2023